Pfizer To Market Strides Generic Injectables

Pfizer and Strides Arcolab entered a new collaboration under which Pfizer will commercialize off-patent sterile injectable and oral products in the U.S. through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Ltd. and Onco Therapies Ltd., two joint ventures between Strides and Aspen, South Africa, in which each owns 50%. Financial terms were not disclosed.

The companies anticipate that the collaboration will deliver 40 off-patent products, many of which are oncology therapeutics, by joining Pfizer’s commercial infrastructure with Strides’s manufacturing capabilities. The first product to be commercialized under this collaboration is expected to launch in 2010.

“This Strides collaboration is new and exciting, and we are encouraged about the potential of this relationship,” said David Simmons, president and general manager of Pfizer’s Established Products Business Unit. “In addition, this agreement brings the total number of products in-licensed by our Established Products Business Unit to more than 200 — resulting in a total business unit portfolio of approximately 600 high-quality, reliable, and cost effective products for patients.”

“Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options,” said Arun Kumar, Strides founder and managing director. “We have established a reputation for efficient formulation development and technologies, manufacturing, and operational flexibility and are looking forward to bringing these strengths to bear in our collaboration with Pfizer.”